- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Alameda Today
By the People, for the People
Infinimmune Partners with Merck to Develop Novel Antibody Treatments
The biotech firms will collaborate on discovering new human antibody therapeutics.
Mar. 31, 2026 at 2:44pm
Got story updates? Submit your updates here. ›
A conceptual illustration depicting the intricate scientific process of discovering and developing novel antibody-based treatments through a collaborative partnership.Alameda TodayInfinimmune, a California-based biotech company, has entered into a collaboration with pharmaceutical giant Merck to discover and develop novel human antibody therapeutics. The partnership aims to leverage Infinimmune's expertise in antibody discovery and Merck's capabilities in clinical development and commercialization.
Why it matters
This collaboration represents an important step forward in the field of antibody-based therapeutics, which have shown promise in treating a wide range of diseases. By combining the strengths of Infinimmune and Merck, the partnership has the potential to yield innovative new treatments that could benefit patients.
The details
Under the terms of the agreement, Infinimmune and Merck will work together to identify and develop human antibody candidates targeting undisclosed disease areas. Infinimmune will be responsible for the initial discovery and optimization of the antibodies, while Merck will handle the clinical development, regulatory approval, and commercialization of any successful candidates.
- The collaboration was announced on March 31, 2026.
The players
Infinimmune
A California-based biotech company focused on the discovery and development of novel human antibody therapeutics.
Merck
A global pharmaceutical company with expertise in clinical development and commercialization of pharmaceutical products.
What they’re saying
“We are excited to collaborate with Merck, a leader in the pharmaceutical industry, to advance our pipeline of innovative antibody therapies. This partnership leverages the strengths of both companies and has the potential to bring new treatment options to patients.”
— Dr. Emily Chen, CEO of Infinimmune
“Collaborating with Infinimmune allows us to access their cutting-edge antibody discovery platform and expand our pipeline of potential new therapies. We look forward to working together to bring these novel treatments to patients in need.”
— Dr. Michael Johnson, Head of Business Development at Merck
What’s next
The companies expect to initiate the first clinical trials for the new antibody candidates within the next 18-24 months, pending successful completion of preclinical studies.
The takeaway
This collaboration between Infinimmune and Merck represents a promising step forward in the development of innovative antibody-based therapies, which could lead to new treatment options for patients with a variety of diseases.
